Government vaccine deal includes $300m to boost manufacturing capability

Sally Whyte
Updated September 9 2020 - 1:37pm, first published September 7 2020 - 4:14pm
Clinical trials are so far showing promise. Picture: Shutterstock
Clinical trials are so far showing promise. Picture: Shutterstock

Manufacturing two different kinds of vaccines is "complicated technically", but biotech giant CSL is confident it has the capability to do so at the company's Melbourne facility.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options
Sally Whyte

Sally Whyte

Federal Politics Reporter

I report on a range of issues in federal politics and the public service, with a real passion for how decisions made in Canberra affect the lives of Australians.

Get the latest Katherine news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.